[{"id":"90e00a6d-bf2f-470b-9aff-9a2babcf60e1","acronym":"SWOG-S1304","url":"https://clinicaltrials.gov/study/NCT01903811","created_at":"2025-02-26T08:59:23.400Z","updated_at":"2025-02-26T08:59:23.400Z","phase":"Phase 2","brief_title":"S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma","source_id_and_acronym":"NCT01903811 - SWOG-S1304","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 11/21/2017","primary_completion_date":" 11/21/2017","study_txt":" Completion: 03/07/2019","study_completion_date":" 03/07/2019","last_update_posted":"2024-12-20"},{"id":"67d0f4ee-9db1-45eb-830d-0ecad0fc8c25","acronym":"","url":"https://clinicaltrials.gov/study/NCT06249282","created_at":"2024-02-08T14:19:19.346Z","updated_at":"2024-07-02T16:34:59.110Z","phase":"Phase 1","brief_title":"Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06249282","lead_sponsor":"City of Hope Medical Center","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • carfilzomib"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/24/2024","start_date":" 04/24/2024","primary_txt":" Primary completion: 03/19/2026","primary_completion_date":" 03/19/2026","study_txt":" Completion: 03/19/2026","study_completion_date":" 03/19/2026","last_update_posted":"2024-06-04"},{"id":"cc43e353-d912-4b11-8947-43a4ef4b102a","acronym":"SINE","url":"https://clinicaltrials.gov/study/NCT02199665","created_at":"2021-01-18T10:17:08.750Z","updated_at":"2024-07-02T16:35:03.805Z","phase":"Phase 1","brief_title":"Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT02199665 - SINE","lead_sponsor":"University of Chicago","biomarkers":" CRBN","pipe":"","alterations":" ","tags":["CRBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/12/2014","start_date":" 06/12/2014","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/25/2024","study_completion_date":" 12/25/2024","last_update_posted":"2024-05-14"},{"id":"dd7ff569-d80c-47b3-9966-fc0126c7d73b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04263480","created_at":"2021-01-18T20:43:06.789Z","updated_at":"2024-07-02T16:35:03.965Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT04263480","lead_sponsor":"Christian Buske","biomarkers":" CD20 • MYD88 • CXCR4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • carfilzomib"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-05-14"},{"id":"85f3a1ec-2757-468c-a247-bc4c8aeb7a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01941316","created_at":"2021-01-18T08:47:22.528Z","updated_at":"2024-07-02T16:35:04.683Z","phase":"Phase 1/2","brief_title":"Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients","source_id_and_acronym":"NCT01941316","lead_sponsor":"Cancer Research and Biostatistics Clinical Trials Consortium","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2024-05-09"},{"id":"7a7e78ae-33bd-4583-a3bd-e69587f5d1ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556332","created_at":"2021-01-18T17:30:18.830Z","updated_at":"2024-07-02T16:35:14.241Z","phase":"Phase 2","brief_title":"A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT03556332","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-03-18"},{"id":"2d84bdc7-c6f6-41e1-b766-7bba4beee15a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031730","created_at":"2021-01-18T14:55:20.440Z","updated_at":"2024-07-02T16:35:14.475Z","phase":"Phase 1","brief_title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03031730","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • navtemadlin (KRT-232) • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/14/2018","start_date":" 06/14/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-15"},{"id":"0b154df6-4ebb-42ce-a9c2-2bdabd8ac5fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06115135","created_at":"2023-11-02T15:13:03.515Z","updated_at":"2024-07-02T16:35:22.451Z","phase":"Phase 2","brief_title":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06115135","lead_sponsor":"Oncotherapeutics","biomarkers":" BCL2 • TNFA","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-24"},{"id":"f98339f3-8da6-4706-ab29-7a338e6db7fa","acronym":"TTI-622-01","url":"https://clinicaltrials.gov/study/NCT03530683","created_at":"2021-07-15T16:53:02.099Z","updated_at":"2024-07-02T16:35:25.423Z","phase":"Phase 1","brief_title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","source_id_and_acronym":"NCT03530683 - TTI-622-01","lead_sponsor":"Pfizer","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 09/11/2024","primary_completion_date":" 09/11/2024","study_txt":" Completion: 09/11/2024","study_completion_date":" 09/11/2024","last_update_posted":"2023-12-22"},{"id":"5fbd1607-3a0e-4647-9158-4e60480d4470","acronym":"ISABEL","url":"https://clinicaltrials.gov/study/NCT04965155","created_at":"2021-07-16T13:53:20.587Z","updated_at":"2024-07-02T16:35:25.810Z","phase":"Phase 2","brief_title":"A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)","source_id_and_acronym":"NCT04965155 - ISABEL","lead_sponsor":"EMN Research Italy","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/21/2021","start_date":" 03/21/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2023-12-19"},{"id":"7465a53d-edcc-499b-8a80-50f901ea6413","acronym":"HO147SMM","url":"https://clinicaltrials.gov/study/NCT03673826","created_at":"2021-01-18T18:01:13.776Z","updated_at":"2024-07-02T16:35:30.805Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM","source_id_and_acronym":"NCT03673826 - HO147SMM","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" PTPRC • NCAM1","pipe":"","alterations":" ","tags":["PTPRC • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/19/2018","start_date":" 11/19/2018","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-11-01"},{"id":"f0c0819b-4a0c-40e5-b044-815d617e97e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01959698","created_at":"2021-01-18T08:54:19.441Z","updated_at":"2024-07-02T16:35:41.807Z","phase":"Phase 1","brief_title":"Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT01959698","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • carfilzomib • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 04/17/2014","start_date":" 04/17/2014","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-27"},{"id":"4ee1845e-942c-47fc-8e6c-1b855d846664","acronym":"","url":"https://clinicaltrials.gov/study/NCT02204241","created_at":"2021-01-26T20:52:45.593Z","updated_at":"2024-07-02T16:35:44.218Z","phase":"Phase 1/2","brief_title":"Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients","source_id_and_acronym":"NCT02204241","lead_sponsor":"European Myeloma Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • carfilzomib • dexamethasone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2023-06-30"},{"id":"5766f363-23d7-4ddf-aa99-822a48d173b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02185820","created_at":"2021-02-04T20:52:56.667Z","updated_at":"2024-07-02T16:35:44.252Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)","source_id_and_acronym":"NCT02185820","lead_sponsor":"European Myeloma Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-06-30"},{"id":"f22b88d8-7426-4a53-a629-86b06e924f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03091127","created_at":"2021-01-18T15:13:44.772Z","updated_at":"2024-07-02T16:35:59.306Z","phase":"","brief_title":"Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe","source_id_and_acronym":"NCT03091127","lead_sponsor":"Amgen","biomarkers":" B2M","pipe":"","alterations":" ","tags":["B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 705","initiation":"Initiation: 03/14/2017","start_date":" 03/14/2017","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/17/2020","study_completion_date":" 03/17/2020","last_update_posted":"2022-12-12"},{"id":"3a0c49c1-727b-492b-bc54-7034bb716618","acronym":"KMM1911","url":"https://clinicaltrials.gov/study/NCT05497102","created_at":"2022-08-15T11:10:45.029Z","updated_at":"2024-07-02T16:36:05.577Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT","source_id_and_acronym":"NCT05497102 - KMM1911","lead_sponsor":"Samsung Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-08-12"},{"id":"614e8a26-5980-4e85-8285-bcb5a81fc5e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01813227","created_at":"2021-01-18T08:02:42.490Z","updated_at":"2024-07-02T16:36:12.759Z","phase":"Phase 2","brief_title":"A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531","source_id_and_acronym":"NCT01813227","lead_sponsor":"Hackensack Meridian Health","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • carfilzomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 09/01/2014","primary_completion_date":" 09/01/2014","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2022-04-13"},{"id":"019e5c1f-7cc6-4bf5-9b54-11b80b290251","acronym":"","url":"https://clinicaltrials.gov/study/NCT03375567","created_at":"2021-01-29T07:16:40.130Z","updated_at":"2024-07-02T16:36:16.671Z","phase":"","brief_title":"Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone","source_id_and_acronym":"NCT03375567","lead_sponsor":"Yale University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2022-02-24"},{"id":"749fedcd-f229-430a-85bb-edecfae0c460","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137523","created_at":"2021-01-18T20:12:24.654Z","updated_at":"2024-07-02T16:36:26.170Z","phase":"","brief_title":"Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression","source_id_and_acronym":"NCT04137523","lead_sponsor":"University of Turin, Italy","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • pomalidomide • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 08/12/2019","primary_completion_date":" 08/12/2019","study_txt":" Completion: 09/15/2022","study_completion_date":" 09/15/2022","last_update_posted":"2021-08-18"},{"id":"f60e6b64-d4a6-4c87-b498-d69b76e6150f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01402284","created_at":"2021-01-18T05:45:42.710Z","updated_at":"2025-02-25T14:32:59.232Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","source_id_and_acronym":"NCT01402284","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 07/21/2011","start_date":" 07/21/2011","primary_txt":" Primary completion: 07/10/2016","primary_completion_date":" 07/10/2016","study_txt":" Completion: 09/24/2020","study_completion_date":" 09/24/2020","last_update_posted":"2021-03-02"},{"id":"f69d13e2-b2d9-4353-a315-4e5c417f3065","acronym":"","url":"https://clinicaltrials.gov/study/NCT01775930","created_at":"2021-01-18T07:49:54.338Z","updated_at":"2024-07-02T16:36:49.242Z","phase":"Phase 2","brief_title":"Carfilzomib in Refractory Renal Cell Carcinoma (RCC)","source_id_and_acronym":"NCT01775930","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 01/18/2019","primary_completion_date":" 01/18/2019","study_txt":" Completion: 01/18/2019","study_completion_date":" 01/18/2019","last_update_posted":"2020-03-04"},{"id":"8ad2139c-3dd6-4c2a-b15c-48f1cf748671","acronym":"","url":"https://clinicaltrials.gov/study/NCT02148913","created_at":"2021-01-18T09:59:05.855Z","updated_at":"2024-07-02T16:37:00.618Z","phase":"Phase 1","brief_title":"Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma","source_id_and_acronym":"NCT02148913","lead_sponsor":"Spectrum Health Hospitals","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • bendamustine • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2019-04-12"},{"id":"028a3521-3d7f-488f-ba33-6ac4ecf0ae4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01470196","created_at":"2021-01-18T06:07:23.404Z","updated_at":"2024-07-02T16:37:05.175Z","phase":"Phase 2","brief_title":"Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia","source_id_and_acronym":"NCT01470196","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2018-11-20"},{"id":"fbbfb018-bca3-4609-93c1-aaf1678cb7a9","acronym":"CARFI","url":"https://clinicaltrials.gov/study/NCT02572492","created_at":"2021-01-18T12:27:54.095Z","updated_at":"2024-07-02T16:37:07.782Z","phase":"Phase 2","brief_title":"Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support","source_id_and_acronym":"NCT02572492 - CARFI","lead_sponsor":"Henrik Gregersen","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • carfilzomib • melphalan • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 04/23/2018","primary_completion_date":" 04/23/2018","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2018-08-17"}]